Drug
Astegolimab clinical trials
Also written MSTT1041A and RO7187807.
- studies test it
- 10
- open now
- 0
- in phase 3
- 2
- first study started
- 2013
How studies write it
Studies that test it under each name
Name
Studies by the year they started
10 studies that test it; most in 2013 (1)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 5
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
Genentech, Inc. (4) · Hoffmann-La Roche (3) · Amgen (2) · University of Leicester (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses astegolimab is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary DiseaseCompletedPhase 2Genentech, Inc.NCT05037929Written as Astegolimab
- A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)Active, not recruitingPhase 3Hoffmann-La RocheNCT05878769Written as Astegolimab
- A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary DiseaseActive, not recruitingPhase 3Hoffmann-La RocheNCT05595642Written as Astegolimab
- A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy SubjectsCompletedPhase 1Genentech, Inc.NCT06462118Written as Astegolimab
- A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic DermatitisCompletedPhase 2Genentech, Inc.NCT03747575Written as MSTT1041A
- A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe AsthmaCompletedPhase 2Hoffmann-La RocheNCT02918019Written as MSTT1041A
- Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP)CompletedPhase 2University of LeicesterNCT03615040Written as MSTT1041A
- A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 PneumoniaCompletedPhase 2Genentech, Inc.NCT04386616Written as MSTT1041A
- A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.CompletedPhase 1AmgenNCT01928368Written as AMG 282
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal PolypsCompletedPhase 1AmgenNCT02170337Written as AMG 282
Codes
What other systems call astegolimab · ClinicalTrials.gg INT001457
- MeSH (NLM) C000711667astegolimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 27TW751DTHASTEGOLIMABConfirmed FDA, NLM
- NCI Thesaurus C171824AstegolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711667 | astegolimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 27TW751DTH | ASTEGOLIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C171824 | Astegolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.